Hanson & Doremus Investment Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $113K | Hold |
525
| – | – | 0.01% | 259 |
|
|
2026
Q1 | $96K | Hold |
525
| – | – | 0.01% | 264 |
|
|
2025
Q4 | $92K | Hold |
525
| – | – | 0.01% | 265 |
|
|
2025
Q3 | $74K | Hold |
525
| – | – | 0.01% | 288 |
|
|
2025
Q2 | $66K | Hold |
525
| – | – | 0.01% | 300 |
|
|
2025
Q1 | $72K | Hold |
525
| – | – | 0.01% | 285 |
|
|
2024
Q4 | $80K | Hold |
525
| – | – | 0.01% | 262 |
|
|
2024
Q3 | $102K | Hold |
525
| – | – | 0.02% | 242 |
|
|
2024
Q2 | $122K | Hold |
525
| – | – | 0.02% | 219 |
|
|
2024
Q1 | $113K | Hold |
525
| – | – | 0.02% | 232 |
|
|
2023
Q4 | $136K | Sell |
525
-76
| -13% | -$18.7K | 0.03% | 211 |
|
|
2023
Q3 | $154K | Hold |
601
| – | – | 0.03% | 195 |
|
|
2023
Q2 | $171K | Hold |
601
| – | – | 0.04% | 189 |
|
|
2023
Q1 | $167K | Hold |
601
| – | – | 0.04% | 189 |
|
|
2022
Q4 | $166K | Hold |
601
| – | – | 0.04% | 191 |
|
|
2022
Q3 | $160K | Hold |
601
| – | – | 0.04% | 194 |
|
|
2022
Q2 | $123K | Hold |
601
| – | – | 0.03% | 223 |
|
|
2022
Q1 | $127K | Hold |
601
| – | – | 0.03% | 237 |
|
|
2021
Q4 | $144K | Hold |
601
| – | – | 0.03% | 216 |
|
|
2021
Q3 | $170K | Buy |
601
+76
| +14% | +$24.9K | 0.04% | 191 |
|
|
2021
Q2 | $149K | Sell |
525
-76
| -13% | -$23K | 0.04% | 182 |
|
|
2021
Q1 | $168K | Buy |
601
+76
| +14% | +$20.5K | 0.04% | 194 |
|
|
2020
Q4 | $129K | Hold |
525
| – | – | 0.03% | 212 |
|
|
2020
Q3 | $149K | Hold |
525
| – | – | 0.04% | 182 |
|
|
2020
Q2 | $140K | Hold |
525
| – | – | 0.04% | 182 |
|
|
2020
Q1 | $166K | Hold |
525
| – | – | 0.06% | 165 |
|
|
2019
Q4 | $156K | Hold |
525
| – | – | 0.04% | 190 |
|
|
2019
Q3 | $122K | Hold |
525
| – | – | 0.04% | 213 |
|
|
2019
Q2 | $123K | Sell |
525
-64
| -11% | -$14.8K | 0.04% | 214 |
|
|
2019
Q1 | $139K | Buy |
589
+64
| +12% | +$20.2K | 0.05% | 200 |
|
|
2018
Q4 | $158K | Hold |
525
| – | – | 0.06% | 179 |
|
|
2018
Q3 | $185K | Hold |
525
| – | – | 0.06% | 179 |
|
|
2018
Q2 | $152K | Sell |
525
-47
| -8% | -$13.2K | 0.05% | 192 |
|
|
2018
Q1 | $157K | Buy |
572
+47
| +9% | +$14.6K | 0.05% | 196 |
|
|
2017
Q4 | $167K | Hold |
525
| – | – | 0.06% | 184 |
|
|
2017
Q3 | $164K | Hold |
525
| – | – | 0.06% | 186 |
|
|
2017
Q2 | $142K | Hold |
525
| – | – | 0.05% | 193 |
|
|
2017
Q1 | $144K | Hold |
525
| – | – | 0.06% | 192 |
|
|
2016
Q4 | $149K | Hold |
525
| – | – | 0.06% | 182 |
|
|
2016
Q3 | $164K | Hold |
525
| – | – | 0.08% | 170 |
|
|
2016
Q2 | $127K | Hold |
525
| – | – | 0.06% | 187 |
|
|
2016
Q1 | $137K | Hold |
525
| – | – | 0.06% | 182 |
|
|
2015
Q4 | $161K | Hold |
525
| – | – | 0.07% | 176 |
|
|
2015
Q3 | $153K | Hold |
525
| – | – | 0.07% | 173 |
|
|
2015
Q2 | $212K | Sell |
525
-25
| -5% | -$10K | 0.09% | 160 |
|
|
2015
Q1 | $232K | Hold |
550
| – | – | 0.1% | 156 |
|
|
2014
Q4 | $187K | Hold |
550
| – | – | 0.08% | 169 |
|
|
2014
Q3 | $182K | Hold |
550
| – | – | 0.08% | 172 |
|
|
2014
Q2 | $173K | Hold |
550
| – | – | 0.08% | 175 |
|
|
2014
Q1 | $168K | Hold |
550
| – | – | 0.08% | 177 |
|
|
2013
Q4 | $154K | Hold |
550
| – | – | 0.07% | 178 |
|
|
2013
Q3 | $132K | Hold |
550
| – | – | 0.07% | 176 |
|
|
2013
Q2 | $118K | Buy |
+550
| New | +$118K | 0.06% | 175 |
|
Other funds holding BIIB
Hanson & Doremus Investment Management's BIIB Position: Q2 2026 in Review
Hanson & Doremus Investment Management held its Biogen (BIIB) position steady in Q2 2026 at 525 shares worth $113K. The position accounts for 0.01% of the portfolio, ranked #259.
Hanson & Doremus Investment Management first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $232K in Q1 2015. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Hanson & Doremus Investment Management held 525 shares of Biogen worth $113K as of Q2 2026.
- Hanson & Doremus Investment Management left its Biogen share count unchanged in Q2 2026.
- Biogen made up 0.01% of Hanson & Doremus Investment Management's portfolio in Q2 2026, its #259 holding.
- Hanson & Doremus Investment Management first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
- Hanson & Doremus Investment Management's Biogen position peaked at $232K in Q1 2015.
- 1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Hanson & Doremus Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.